CELC
Celcuity Inc.
$65.25
-0.32
(-0.49%)
Mkt Cap
3.19B
Volume
1,314,657
52W Range
53.54-151.02
Sector
Healthcare
Beta
0.16
EPS (TTM)
-4.29 USD
P/E Ratio
-26.39
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (177.04M) | (111.78M) | (63.78M) | (40.37M) | (29.61M) | (9.47M) | (7.36M) | (7.48M) | (6.25M) | (3.31M) | (2.26M) |
| EPS | -3.78 | -2.83 | -2.69 | -2.68 | -2.28 | -0.89 | -0.69 | -0.74 | -0.84 | -0.49 | -0.36 |
| Free Cash Flow | (153.53M) | (83.72M) | (53.91M) | (36.17M) | (20.39M) | (7.24M) | (6.38M) | (6.71M) | (5.19M) | (2.93M) | (2.06M) |
| FCF / Share | -2.92 | -2.12 | -2.28 | -2.35 | -1.52 | -0.70 | -0.62 | -0.66 | -0.70 | -0.44 | -0.33 |
| Operating CF | (153.28M) | (83.47M) | (53.81M) | (36.01M) | (20.31M) | (7.15M) | (6.00M) | (6.08M) | (4.95M) | (2.89M) | (1.98M) |
| Total Assets | 466.56M | 245.12M | 191.22M | 175.70M | 85.91M | 12.96M | 20.28M | 26.03M | 31.97M | 6.06M | 5.30M |
| Total Debt | 195.38M | 97.95M | 37.45M | 35.24M | 14.89M | 262,488 | 256,137 | 25,608 | 0 | 0 | 0 |
| Cash & Equiv | 165.70M | 22.51M | 30.66M | 24.57M | 84.29M | 11.64M | 18.74M | 15.94M | 2.64M | 5.86M | 5.07M |
| Book Value | 100.56M | 115.62M | 139.77M | 133.77M | 68.71M | 11.70M | 19.30M | 25.35M | 31.39M | 5.61M | 5.02M |
| Return on Equity | -1.76 | -0.97 | -0.46 | -0.30 | -0.43 | -0.81 | -0.38 | -0.30 | -0.20 | -0.59 | -0.45 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (78.86M) | (52.84M) | (50.97M) | (43.80M) | (45.27M) | (37.00M) | (36.65M) | (29.79M) | (23.72M) | (21.61M) | (18.85M) | (18.40M) |
| EPS | -1.44 | -0.97 | -0.96 | -0.92 | -1.04 | -0.86 | -0.85 | -0.70 | -0.62 | -0.64 | -0.65 | -0.83 |
| Free Cash Flow | (55.48M) | (55.31M) | (36.45M) | (44.91M) | (36.25M) | (35.91M) | (27.82M) | (20.61M) | (18.13M) | (17.16M) | (18.57M) | (12.80M) |
| FCF / Share | -1.01 | -1.02 | -0.69 | -1.00 | -0.83 | -0.83 | -0.65 | -0.48 | -0.47 | -0.51 | -0.64 | -0.58 |
| Operating CF | (55.43M) | (55.06M) | (36.40M) | (44.82M) | (36.21M) | (35.85M) | (27.77M) | (20.56M) | (18.07M) | (17.07M) | (18.54M) | (12.75M) |
| Total Assets | 828.22M | 410.16M | 466.56M | 476.00M | 183.59M | 218.13M | 245.12M | 273.04M | 292.54M | 188.18M | 191.22M | 142.38M |
| Total Debt | 754.38M | 195.58M | 195.38M | 320.35M | 99.42M | 98.71M | 97.95M | 97.19M | 96.51M | 37.93M | 37.45M | 36.97M |
| Cash & Equiv | 182.05M | 145.19M | 165.70M | 74.25M | 46.35M | 16.48M | 22.51M | 12.60M | 30.46M | 31.21M | 30.66M | 25.76M |
| Book Value | (12.78M) | 53.52M | 100.56M | 116.96M | 44.38M | 86.67M | 115.62M | 149.71M | 176.68M | 133.74M | 139.77M | 92.90M |
| Return on Equity | N/A | -0.99 | -0.51 | -0.37 | -1.02 | -0.43 | -0.32 | -0.20 | -0.13 | -0.16 | -0.13 | -0.20 |
CELC News
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026
New Strong Sell Stocks for October 14th
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
Celcuity Appoints David Gryska To Its Board Of Directors
Celcuity (NASDAQ:CELC) Shares Gap Up – Time to Buy?
Why Celcuity Stock Was a Winner on Wednesday
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript
Celcuity To Participate in Upcoming Investor Conferences
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer